Dawn Lee
YOU?
Author Swipe
View article: Randomized controlled trial reporting guidelines should be updated to include information on subsequent treatments
Randomized controlled trial reporting guidelines should be updated to include information on subsequent treatments Open
This paper highlights the urgent need to update randomized controlled trial reporting guidelines to include consistent and detailed data on subsequent treatments, particularly in oncology, where postprogression therapies significantly infl…
View article: How Similar Is Similar Enough? Assessment of Indirect Treatment Comparisons to Support Similarity for National Institute for Health and Care Excellence’s Cost Comparison Route
How Similar Is Similar Enough? Assessment of Indirect Treatment Comparisons to Support Similarity for National Institute for Health and Care Excellence’s Cost Comparison Route Open
Formal methods to assess equivalence in ITC-based cost comparison are emerging but have not yet been applied in practice. We provide recommendations for how these methods and qualitative methods, such as evaluation of the plausibility of c…
View article: NICE’s early value assessment: an external assessment group’s commentary on the challenges and opportunities of NICE’s new life cycle approach to HealthTech
NICE’s early value assessment: an external assessment group’s commentary on the challenges and opportunities of NICE’s new life cycle approach to HealthTech Open
The National Institute for Health and Care Excellence (NICE) early value assessment (EVA) was launched in 2022 as a process to assess new technologies that have the potential to meet an unmet need or demand. The recommendations that result…
View article: Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data
Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data Open
Background: The purpose of this study was to explore the effectiveness of cabozantinib versus sunitinib for the treatment of first-line metastatic renal cell carcinoma in intermediate/poor risk patients. Materials and methods: Retrospectiv…
View article: Testing spatial out-of-sample area of influence for grain forecasting models
Testing spatial out-of-sample area of influence for grain forecasting models Open
We examine the factors that determine if a grain forecasting model fit to one region can be transferred to another region. Prior research has proposed examining the area of applicability (AoA) of a model based on structurally similar chara…
View article: Correction: NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances
Correction: NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances Open
View article: Real world, multicentre patterns of treatment and survival in metastatic renal cell carcinoma with the <scp>UK</scp> Renal Oncology Collaborative (<scp>UK ROC</scp>): Is it time to look favourably on first‐line immunotherapy containing combinations in all <scp>IMDC</scp> groups?
Real world, multicentre patterns of treatment and survival in metastatic renal cell carcinoma with the <span>UK</span> Renal Oncology Collaborative (<span>UK ROC</span>): Is it time to look favourably on first‐line immunotherapy containing combinations in all <span>IMDC</span> groups? Open
Introduction Clinical trials show improved progression‐free survival (PFS) and overall survival (OS) in first‐line metastatic renal cell carcinoma (mRCC) patients with immunotherapy containing systemic anti‐cancer therapies (SACT). However…
View article: NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances
NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances Open
Conflicts of Interest/CompetingInterests Dawn Lee has provided consultancy services to a number of companies unrelated to possible intervention
View article: Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes
Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes Open
Prescribing more efficacious treatments earlier provides a greater opportunity to improve patient outcomes and minimizes treatment failures.
View article: A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales Open
At 12 mg/kg/day and an ICER threshold of £20,000-£30,000, we provide evidence for the cost effectiveness of add-on cannabidiol treatment for patients with TSC-associated seizures aged ≥ 2 years who are refractory to current treatment.
View article: Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis
Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis Open
View article: The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products
The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products Open
Ultimately, moving from a restrictive end-of-life modifier to one based on disease severity is a more equitable approach likely to benefit many therapies, including orphan products. However, NICE's single technology appraisal updates are u…
View article: Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States Open
Approximately, 4% of Stage IV colorectal cancers (CRC) are microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) tumors. Patients with metastatic MSI-H/dMMR CRC receiving conventional therapies experience lower response …
View article: POSC319 Analysis of Treatment Sequences across Seven Immunological Diseases and the Variability in Efficacy for Patients By Disease: Opportunities for Improvement
POSC319 Analysis of Treatment Sequences across Seven Immunological Diseases and the Variability in Efficacy for Patients By Disease: Opportunities for Improvement Open
View article: Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment Open
Objective Autologous stem cell transplantation (ASCT) has improved progression‐free survival (PFS) and overall survival in eligible patients with newly diagnosed multiple myeloma (NDMM); however, relapse occurs. Maintenance therapy with le…
View article: R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study Open
View article: Health-related quality of life and the burden of prolonged seizures in noninstitutionalized children with epilepsy
Health-related quality of life and the burden of prolonged seizures in noninstitutionalized children with epilepsy Open
Health-related quality of life was very poor in many children with epilepsy whose PACS were managed with rescue medication in the community, with learning disability being the most powerful predictor of patients' HRQoL. Mean EQ-5D utility …
View article: PNS217 HOW CENTRAL LIMIT THEOREM RELATES TO THE SELECTION OF DISTRIBUTIONS FOR PROBABILISTIC SENSITIVITY ANALYSIS
PNS217 HOW CENTRAL LIMIT THEOREM RELATES TO THE SELECTION OF DISTRIBUTIONS FOR PROBABILISTIC SENSITIVITY ANALYSIS Open
View article: PCN346 MEAN VERSUS MEDIAN: WHAT DOES NICE CONSIDER TO BE THE MOST APPROPRIATE STATISTIC FOR ESTIMATING SHORT LIFE EXPECTANCY TO SATISFY END-OF-LIFE CRITERIA?
PCN346 MEAN VERSUS MEDIAN: WHAT DOES NICE CONSIDER TO BE THE MOST APPROPRIATE STATISTIC FOR ESTIMATING SHORT LIFE EXPECTANCY TO SATISFY END-OF-LIFE CRITERIA? Open
View article: Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection Open
View article: The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q Open
This case study demonstrates the usefulness and relevance of the application of real-world data when trial data are limited.
View article: PRM135 - DICE FOR NICE? LESSONS FROM A SINGLE TECHNOLOGY APPRAISAL
PRM135 - DICE FOR NICE? LESSONS FROM A SINGLE TECHNOLOGY APPRAISAL Open
View article: Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England Open
The second Key Point for Decision Makers, which reads:
View article: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England Open
View article: The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England Open
Nivolumab is a cost-effective treatment for advanced melanoma patients in England.
View article: Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK
Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK Open
View article: Effect of rescue medication on seizure duration in non-institutionalized children with epilepsy
Effect of rescue medication on seizure duration in non-institutionalized children with epilepsy Open
This study provides the first real-world data that rescue medications administered in the community reduce the duration of PACS in children with epilepsy. Study limitations including potential recall bias are acknowledged.
View article: Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece
Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece Open
This analysis indicates that eplerenone may be a cost-effective option versus standard care accompanied by additional clinical benefits and an added incremental cost at an acceptable, if not low, CE ratio. The results are consistent with t…
View article: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma Open
View article: The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight Open
Estimation of drug costs in health economic evaluation should account for the distribution in weight or BSA to produce accurate results. When patient data are not available, general population data may be used as an alternative.